On Tuesday, Canadian Pacific Railway Limited (USA) (NYSE:CP)’s shares declined -1.21% to $155.24.
Canadian Pacific is well positioned to provide best-in-class service to western Canadian grain shippers during the 2015-2016 crop-year.
CP’s service offering to grain customers is driven by efficiency and creating velocity in the rail portion of the complex grain supply chain. CP’s Dedicated Train Program (DTP), which was introduced last-crop year, provides customers with greater clarity and control of car supply to manage their supply chain. CP anticipates adding more trains to the program this crop year as it responds to greater demand to move grain and grain products from western Canada . In the 2014-2015 crop year, CP moved a record 276,154 carloads (27,849,434 MT) of Canadian grain and grain products from western Canadian origins, up from the previous record crop year of 2013-2014.
CP continues to invest in its network to improve efficiency, create velocity and provide the best service possible to customers. In 2015, CP will spend 21 percent of its revenue on capital expenditures, more than any other Class 1 railroad. Canadian rail rates remain among the lowest in the world, having risen just 6 percent since 2000 even as commodity prices have soared by 166 percent.
Canadian Pacific Railway Limited, through its auxiliaries, operates a transcontinental railway in Canada and the United States. The company provides logistics and supply chain expertise services. It transports bulk commodities, counting grain, coal, fertilizers, and sulphur; and intermodal traffic comprising retail goods in overseas containers that can be transported by train, ship, and truck, in addition to in domestic containers and trailers that can be moved by train and truck.
Diamondback Energy Inc (NASDAQ:FANG)’s shares gained 1.62% to $73.38.
Diamondback Energy, Inc. (FANG) declared the pricing of an underwritten public offering of 2,500,000 shares of its common stock. The 2,500,000 share offering represents a 500,000 share upsize to the originally projected 2,000,000 share offering. The underwriter intends to offer the shares from time to time for sale in one or more transactions on the NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The total gross proceeds of the offering (before underwriter discounts and commissions and estimated offering expenses) will be about $175.6 million. The underwriter has a 30-day option to purchase up to an additional 375,000 shares of common stock from Diamondback.
Diamondback intends to use the net proceeds from this offering to repay a portion of the outstanding borrowings under its revolving credit facility.
Diamondback Energy, Inc., an independent oil and natural gas company, focuses on the acquisition, development, exploration, and exploitation of onshore oil and natural gas reserves in the Permian Basin in West Texas. Its activities are primarily focused on the Clearfork, Spraberry, Wolfcamp, Cline, Strawn, and Atoka formations.
At the end of Tuesday’s trade, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)‘s shares dipped -4.21% to $9.79.
ZIOPHARM Oncology, Inc. (ZIOP) declared financial results for the second quarter ended June 30, 2015, and offered an update on the company’s recent activities.
Recent Highlights
Ad-RTS-hIL-12
Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response, using the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch. In April 2015, ZIOPHARM declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. In May 2015, the Company declared the initiation of a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer.
Both gene therapy trials, which are being conducted at leading centers across the U.S., are presently open and accruing patients. The Company anticipates that early results from each study will be presented at scientific meetings proceeding to year end.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation’s RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index.
DDR Corp (NYSE:DDR), ended its Tuesday’s trading session with 1.02% gain, and closed at $16.91.
DDR Corp. (DDR) declared operating results for the second quarter ended June 30, 2015.
Financial Highlights
- Second quarter operating funds from operations attributable to common shareholders (“Operating FFO”) raised $10.1 million to $111.4 million, or $0.31 per diluted share, contrast to $101.3 million, or $0.28 per diluted share, for the preceding-year comparable period.
- Second quarter net income attributable to common shareholders was $13.0 million, or $0.03 per diluted share, which compares to net income of $67.8 million, or $0.19 per diluted share, for the preceding-year comparable period.
NoteworthyQuarterly Activity
- Generated same store net operating income growth of 3.0% on a pro rata basis.
- Executed 369 new leases and renewals for 2.9 million square feet.
- The annualized base rent per occupied square foot was $14.37 at June 30, 2015 as contrast to $13.72 at June 30, 2014, an enhance of 4.7% on a pro rata basis.
- Generated new leasing spreads of 25.4% on a pro rata basis, and renewal leasing spreads of 7.2% on a pro rata basis.
- The portfolio leased rate was 95.8% at June 30, 2015 and 2014 on a pro rata basis.
- Attained $111 million of wholly-owned prime power centers.
- Sold ten assets totaling $60 million at DDR’s share.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
